Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
36 Cards in this Set
- Front
- Back
|
constant proportion of cell population killed rather than constant number
|
log-kill hypothesis
|
|
|
treatment with cancer chemotherapy at high doses every 3-4 weeks, too toxic to be used continuously
|
pulse therapy
|
|
|
toxic effect of anticancer drug can be lessened by rescue agents
|
rescue therapy
|
|
|
drug used concurrently with toxic anticancer agents to reduce renal precipitation of urates
|
allopurinol
|
|
|
pyrimidine analog that causes "thymine-less death" given with leucovorin rescue
|
5-fluorouracil
|
|
|
drug used in cancer therapy causes Cushing-like synptoms
|
prednisone
|
|
|
side effect of mitomycin
|
SEVERE myelosuppression
|
|
|
MOA of cisplatin
|
alkylating agent
|
|
|
common toxicities of cisplatin
|
nephro and ototoxicity
|
|
|
analog of hypoxanthine, needs HGPRTase for activation
|
6-mercaptopurine (6-MP)
|
|
|
interaction with this drug requires dose reduction of 6-MP
|
allopurinol
|
|
|
may protect against doxorubicin toxicity by scavenging free radicals
|
dexrazoxane
|
|
|
blows DNA (breaks DNA strands), limiting SE is pulmonary fibrosis
|
bleomycin
|
|
|
bleomycin+vinblastine+ etoposide+cisplatin produce almost a 100% response when all agents are used for this neoplasm
|
testicular cancer
|
|
|
MOPP regimen used in Hodgkin's disease
|
mechlorethamine + oncovorin (vincristine) + procarbazine and prednisone
|
|
|
ABVD regimen used for HD, but appears less likely to cause sterility and secondary malignancies than MOPP
|
adriamycin (doxorubicin) + bleomycin, vinblastine + dacarbazine
|
|
|
regimen used for non-Hodgkin's lymphoma
|
COP
-cyclophosphaminde, oncovin (vincristine), and prednisone |
|
|
regimen used for breast cancer
|
CMF
- cyclophosphamide, methotrexate, and fluorouracil -tamoxifen if ER (+) |
|
|
alkylating agent, vesicant that causes tissue damage with extravasation
|
mechlorethamine
|
|
|
anticancer drug also used in RA, produces acrolein in urine that leads to hemorrhagic cystitis
|
cyclophosphamide
|
|
|
prevention of cyclophosphamide induced hemorrhagic cystitis
|
hydration and mercaptoethanesulfonate (MESNA)
|
|
|
microtubule inhibitor that causes peripheral neuropathy, foot drop, and "pins and needles" sensation
|
vincristine
|
|
|
interact with microtubules (unlike vinca which prevents disassembly of tubules) stabilizes tubulin and cells remain frozen in metaphase
|
paclitaxel (taxol)
|
|
|
toxicities include nephrotoxicity and ototoxicity, leading to a severe interaction with aminoglycosides
|
cisplatin
|
|
|
agent similar to cisplatin, less nephrotoxic, but greater myelosuppression
|
carboplatin
|
|
|
converts asparagine to aspartate and ammonia, denies cancer cells of essential AA (asparagine)
|
L-asparaginase
|
|
|
used for hairy cell leukemia; stimulates NK cells
|
interferon alpha
|
|
|
anti-androgen used for prostate cancer
|
flutamide
|
|
|
anti-estrogen used for estrogen receptor (+) breast CA
|
tamoxifen
|
|
|
aromatase inhibitor used in breast CA
|
letrozole, anastrozole
|
|
|
newer estrogen receptor antagonist used in advanced breast CA
|
toremifene (Fareston)
|
|
|
some cell cycle specific anti-cancer drugs
|
bleomycin, vinca, alkaloids, antimetabolites (5-FU, 6-MP, methotrexate, etoposide)
|
|
|
some cell cycle non-specific drugs
|
alkylating agents (mechlorethamine, cyclophosphamide), antibiotics (doxorubicin, daunorubicin), cisplatin, nitrosurea
|
|
|
anti-emetics used in association with anti-cancer drugs that are 5-HT3 antagonist
|
ondansetron, granisetron
|
|
|
nitrosureas with high lipophilicity, used for brain tumors
|
carmustine (BCNU) and lomustine (CCNU)
|
|
|
produces disulfiram-like reaction with ethanol
|
procarbazine
|
